Takeda Pharmaceutical Company Limited (TAK) Stock Overview
Explore Takeda Pharmaceutical Company Limited’s financial performance, market position, analyst ratings, and future outlook.
Takeda Pharmaceutical Company Limited (TAK)
Key Financials
Key Financials
Market Cap
55.4B
P/E Ratio
48.25
EPS (TTM)
$1.39
ROE
0.02%
TAK Stock Analysis & Investment Overview (NYSE)
Our AI-powered analysis of Takeda Pharmaceutical Company Limited (NYSE: TAK) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Takeda Pharmaceutical Company Limited's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TAK on the NYSE shows an RSI of 58.35, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $17.52 for the NYSE listing.
Key metrics behind Takeda Pharmaceutical Company Limited's NYSE-traded stock include a P/E ratio of 48.25 and a market capitalization of 55.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TAK on the NYSE.